human Cancer Proteome Project (Cancer-HPP)

• Hui Zhang (Chair), John Hopkins University, Baltimore
• Edouard Nice (Co-chair), Monash University, Australia
• Connie Jimenez (Co-chair), VU University Medical Center, Amsterdam
• Chris Kinsinger (NIH/NCI)

Cancer HPP partners with NCI's Clinical Proteome Tumor Analysis Consortium (CPTAC).

• Delineate cancer proteomes versus matched normal/ premalignant
• Identify tumor-type specific signatures by comparison of multiple tumor types through data sharing and analysis
• Deposition of raw data of cancer proteomics datasets after publication in the public domain (eg., Proteome Exchange) to enable meta-analyses

Highlights in the field of cancer proteomics:

1. The proteomic landscape of several major human tumors (breast, colorectal, and ovarian cancer) was analyzed by the NCI-Cancer Proteomics Tumor Analysis Consortium (CPTAC) and published in high impact papers.  Importantly, all data are publicly available
2. CPTAC goes international: agreements in place to characterize additional tumors in Australia, Canada, Germany, Japan, South Korea, Switzerland, Taiwan, and United States

Upcoming Events:

RCPA: Clinical Mass Spectrometry Forum - Clinical Proteomics, Sydney, Australia, Feb 2019

RCPA: Pathology Update 2019, Melbourne, Australia, Feb 2019

The Omics Revolution: Beyond the Genome. Oaks Resort, Port Douglas, Queensland, Australia. 8th Sept 2019

AACR, Atlanta, GA, USA – Mar 30 – Apr 2, 2019

ASMS, Atlanta, GA, USA – June 3 – 7, 2019

EuPA, Potsdam, Germany, May 24-28, 2019

Further reading:

Tissue and plasma proteomics for early stage cancer detection. Peng L, Cantor DI, Huang C, Wang K, Baker MS, Nice EC. Mol Omics. 2018 Dec 3;14(6):405-423.

Evaluation of NCI-7 Cell Line Panel as a Reference Material for Clinical Proteomics. Clark DJ, Hu Y, Bocik W, Chen L, Schnaubelt M, Roberts R, Shah P, Whiteley G, Zhang H. Journal of Proteome Research. 2018; 17 (6), 2205-2215.

Quality Assessments of Long-term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues. Zhou J-Y, Chen L, Zhang B, Tian Y, Liu T, Thomas SN, Chen L, Schnaubelt M, Boja E, Hiltke T, Kinsinger CR, Rodriguez H, Davies SR, Li S, Snider JE, Erdmann-Gilmore P, Tabb DL, Townsend RR, Ellis MJ, Rodland RD, Smith RD, Carr SA, Zhang Z, Chan DW, Zhang H. Journal of Proteome Research, 2017; 16 (12): 4523-4530.

Targeted proteomic analyses of Histone H4 acetylation changes associated with homologous recombination deficient high-grade serous ovarian carcinomas. Thomas SN, Chen L, Liu L, Hoti N, Zhang H. J Proteome Res. 2017; 16 (10): 3704-3710.

Proteome-wide tyrosine phosphorylation analysis reveals dysregulated signaling pathways in ovarian tumors. Molecular & Cellular Proteomics. Song G, Chen L, Zhang B, Song Q, Yu Y, Moore C, Wang T-L, Shih I-M, Zhang H, Chan D, Zhang Z, Zhu H. 2018; mcp. RA118. 000851.

Are you involved in Cancer Research? Interested in the latest initiatives of the Cancer-HPP? If so, subscribe to the Cancer-HPP mailing list to receive initiative updates, news and meeting details.

The Cancer-HPP key aims are to:

1. Characterize proteomes, proteome forms, and protein networks from different cancers and the matched non-cancers through coordinated efforts of specimen collections and data acquisitions.

2. Identify cancer-specific proteins, protein forms, or protein networks from each cancer type and cancer-type-specific proteins, protein forms, and protein networks by comparison of multiple cancer types through data deposition, sharing, and data analysis.

3. Determine the protein-specific or protein-isoform-specific changes of cancer through the correlation studies of genomic and proteomic data through the comparison to the existing genomic data or the genomic data collected from each specimen.

4. Develop targeted assays to measure protein- or protein-form-specific changes for each tumor type to support the analysis of complex biological networks or clinical specimens underlying different disease processes.

5. Disseminate assays to the discovery labs to apply the targeted assays to the specimens from discovery specimens to verify the changes from discovery phase.

6. Validate the protein, protein forms, or protein network changes in independent specimens.

Click here to subscribe.